Title:
T CELL RECEPTOR FOR IDENTIFYING EBV LMP2 ANTIGEN AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/092452
Kind Code:
A1
Abstract:
The present invention provides a T cell receptor (TCR) for specifically identifying an EBV LMP2 antigen, a conjugate and a fusion protein comprising the TCR, an immune cell expressing the TCR, a T cell drug containing the TCR, and the use of the TCR in preventing or treating EBV-related diseases (such as EBV-positive tumors or EBV-related lymphoproliferative disorders).
Inventors:
MOU NAN (CN)
YU YUE (CN)
YUAN JIJUN (CN)
YU YUE (CN)
YUAN JIJUN (CN)
Application Number:
PCT/CN2021/133480
Publication Date:
June 01, 2023
Filing Date:
November 26, 2021
Export Citation:
Assignee:
SHANGHAI GENBASE BIOTECHNOLOGY CO LTD (CN)
International Classes:
C07K14/725; A61K38/17; A61P31/22; A61P35/00; C07K19/00; C12N5/10; C12N15/12; C12N15/63; C12N15/861; C12N15/866; C12N15/867
Foreign References:
| CN113621071A | 2021-11-09 | |||
| CN108602875A | 2018-09-28 | |||
| CN112940108A | 2021-06-11 | |||
| CN113166224A | 2021-07-23 | |||
| CN109306005A | 2019-02-05 |
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF: